NIMBUS NAMED BY FIERCEBIOTECH AS ONE OF THE "FIERCE 15" OF 2013

NIMBUS NAMED BY FIERCEBIOTECH AS ONE OF THE "FIERCE 15" OF 2013

CAMBRIDGE, Mass. – September 24, 2013 – Nimbus Discovery, LLC, a biotechnology company discovering novel medicines against exciting but previously inaccessible disease targets, today announced that the company has been named by FierceBiotech as one of 2013's Fierce 15, designating it as one of the most promising private biotechnology companies in the industry.  Every year FierceBiotech evaluates hundreds of private companies from around the world for its annual Fierce 15 list, which is based on a variety of factors such as the strength of its technology, partnerships, venture backers and a competitive market position. The Fierce 15 celebrates the spirit of being "fierce" – championing innovation and creativity, even in the face of intense competition.   A complete list of "Fierce 15" companies – the online newsletter's eleventh annual selection – is available online at FierceBiotech.com.

"Within two years of its Series A financing, Nimbus Discovery has grown from a great idea with an interesting list of investors to an exciting company on the verge of clinical trials with drugs against some of the most exciting targets in oncology and other fields," says FierceBiotech Executive Editor Ryan McBride.

"Nimbus is honored to be chosen by the editors of FierceBiotech as one of this year's Fierce 15 – a welcomed acknowledgement of our company's innovative and creative drug discovery approach," said Jonathan Montagu, Vice President, Business Development and Operations of Nimbus.

"Nimbus is successfully solving hard chemistry problems for the most sought-after disease targets in an effort to deliver breakthrough medicines," said Rosana Kapeller, M.D., Ph.D., Chief Scientific Officer of Nimbus.  "We believe that achieving this goal requires a fundamentally deeper understanding of drug pharmacology.  Our progress to date has been enabled through cutting-edge technology and the insights of our industry-leading team, Scientific Advisory Board, Board of Directors and drug-discovery collaborators."

Using its computationally-driven, structure-based drug discovery engine, Nimbus has assembled an impressive track record of delivering significant value from the company's scientific programs:

  • Two industry-leading research collaborations:
    • Shire plc – focused on co-development of first-in-class small molecule treatments for several rare genetic diseases known as lysosomal storage disorders (LSDs);
    • Monsanto – focused on co-development of broad-spectrum fungicides, with new modes of action, that will help farmers control diseases and promote overall plant health;
  • First to identify true drivers of potency / selectivity for important disease targets (ACC and IRAK4);
  • Industry-leading productivity metrics for hard targets: in silico screen to drug candidate in 16 months for ACC;
  • First-and-only collaboration of its type with co-founding partner Schrodinger, the leader in computer simulation technology;
  • First prospective use of solvation technology in multiple drug discovery programs;
  • Unprecedented use of massively parallel cloud-computing (50k clusters);

About FierceBiotech

FierceBiotech is an internationally-recognized, daily, free-email newsletter and web resource providing the latest biotech news, articles, and resources related to clinical trials, drug discovery, FDA approval and regulation, biotech company deals and more. Reaching more than 100,000 biotech and pharma industry professionals, FierceBiotech provides subscribers with an authoritative analysis of the day's top stories.

About Nimbus

Nimbus Discovery, a biotechnology company, harnesses cutting-edge computational technologies to uncover breakthroughs in small molecule pharmacology. Nimbus focuses on medically important and highly sought-after disease targets that have proven inaccessible to traditional industry approaches. Nimbus' robust pre-clinical pipeline includes novel agents for the treatment of cancer, metabolic disease and inflammation. The company is organized as a constellation of small, nimble teams of experienced drug-hunters deployed across program-focused subsidiary companies. Each team is freed from conventional barriers to scientific success, chartered to create solutions, and geared for program asset deals with leading pharmaceutical companies. Founded in 2009, Nimbus partnered with Schrödinger to invent and apply a physics-based approach that establishes a new standard for rational drug design. Nimbus is backed by world-class life science investors, including Atlas Venture, SR One, Lilly Ventures and Bill Gates. For more information please visit www.nimbusdiscovery.com.

Contact:

Nimbus Discovery LLC
Jonathan Montagu
Vice President, Business Development & Operations
Phone: +1 (857) 999-2009
Email: [email protected]

Maureen L. Suda (Media)
Suda Communications LLC
Phone: + 1 (585) 387-9248

Suggested Articles

Researchers are studying the retrovirus KoRV-A, which is spreading among koalas, to gain new insights into how DNA evolves.

Shionogi and Hsiri Therapeutics first joined forces last year in a licensing and R&D deal focused on tuberculosis and non-tuberculous lung infections.

The efficacy results suggest the experimental oral therapy, abrocitinib, has a shot at challenging the blockbuster biologic incumbent.